<DOC>
	<DOCNO>NCT00462774</DOCNO>
	<brief_summary>Cell transplantation treatment heart failure novel field translational research offer perspective develop curative approach regenerate `` rejuvenate '' lose and/or diseased myocardium induce growth new blood vessel . Based safety preliminary efficacy test previous trial , stringent efficacy test perform study . Sixty patient myocardial infarction past need bypass surgery ongoing coronary artery disease undergo either bypass surgery placebo treatment bypass surgery injection CD133 bone marrow cell directly heart muscle . The study fully blind , i.e . neither patient surgeon know substance inject ( placebo cell product ) . Patients follow 6 month various heart function measurement perform .</brief_summary>
	<brief_title>Bypass Surgery CD133 Marrow Cell Injection Treatment Ischemic Heart Failure</brief_title>
	<detailed_description>Beginning 2001 , phase-1 equivalent feasibility safety evaluation intramyocardial injection autologous CD133+ bone marrow cell elective CABG surgery conduct Rostock University . No procedure-related adverse event observe improvement myocardial contractility perfusion . It decide proceed control efficacy testing , compare outcome standard CABG surgery CABG CD133+ cell injection . The result study indicate additional cell injection yield well leave ventricular contractility CABG alone ( LVEF = 47.1±8 % vs. 41.3±9 % 6 month ) . Although result encouraging , trial several limitation hamper interpretation data . Most notably , sham-injection placebo material perform control group , standard 2D echocardiography serve measurement global LV contractility . A stringent efficacy test need large-scale clinical multicenter trial justify . Therefore , prospective , full blind , randomize , placebo-controlled trial conduct Deutsches Herzzentrum Berlin Berlin ( DHZB ) , employ current state-of-the art measurement global regional LV contractility cardiac MRI . The following hypothesis test : `` Patients undergo CABG &amp; CD133+ cell injection high LV ejection fraction patient undergo CABG alone , measure 6 month operation '' . A power analysis base previous trial result indicate 29 patient per group need enrol reject null-hypothesis sufficient statistical power . A total 60 patient therefore enrol study randomize undergo either CABG surgery injection placebo conjunction intramyocardial injection autologous CD133+ enrich bone marrow cell . Bone marrow harvest one day prior surgery CD133-enriched cell product ( placebo ) prepare on-campus . The following day , bypass surgery perform study substance inject border zone infarcted myocardium . Random allocation perform cell production facility , neither patient surgeon person involve follow-up examination know whether cell product placebo administer . The primary outcome parameter ( LVEF 6 month ) measure cardiac MRI , secondary outcome parameter include myocardial perfusion , exercise capacity , quality-of-life assessment .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<criteria>Coronary artery disease indication CABG surgery Reduced global leave ventricular ejection fraction transthoracic echocardiography rest ( EF ≤ 35 % ) Presence localize akinetic/hypokinetic/hypoperfused area LV myocardium define target area Informed consent patient Age &gt; 18 year Emergency operation Presence aortic valve disease require concomitant valve replacement Debilitating disease : Degenerative neurologic disorder , psychiatric disease , terminal renal failure require dialysis , previous organ transplantation , active malignant neoplasia History ventricular arrhythmia ( ≥ Lown III ) Impaired ability comprehend study information Absent inform write consent Apparent infection ( CRP ≥ 20 mg/L , fever ( ≥38.5° C ) Acute myocardial infarction contraindication MRI assessment Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>CD133</keyword>
	<keyword>Bypass surgery</keyword>
	<keyword>Stem cell</keyword>
</DOC>